G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.19 USD
+0.20 (6.69%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 201 - 220 ( 356 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
More Positive Data for Trilaciclib in mTNBC and Rintodestrant at SABCS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Final Trilaciclib in mTNBC OS Data and New Rintodestrant Monotherapy in ER+, HER2- Breast Cancer Findings at 2020 SABCS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Rinto Update in Q4, Trila PDUFA February 15th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q20 Results; Approval and Launch of Trilaciclib Expected 1Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Rinto Update in Q4, Trila PDUFA February 15th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Abstracts Released for Trilaciclib Presentations at the North American Conference on Lung Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Presentations at the NACLC Meeting on Myelopreserving Drug Trilaciclib
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
CEO Succession Plan Announced; New CEO to Take the Reins in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E